Polymorphism in liver-stage malaria vaccine candidate proteins: immune evasion and implications for vaccine design

References

• Who. World Malaria Report 2013. World Health Organization; 2013. p. 1–255. http://www.who.int/malaria/publications/world_malaria_report_2013/report/en/
   Google Scholar
• Frevert U, Krzych U. Plasmodium cellular effector mechanisms and the hepatic microenvironment. Front Microbiol. 2015;6:482.
   PubMed Web of Science ®Google Scholar
• Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31–45.
   PubMed Web of Science ®Google Scholar
• Hafalla JC, Silvie O, Matuschewski K. Cell biology and immunology of malaria. Immunol Rev. 2011;240(1):297–316.
   PubMed Web of Science ®Google Scholar
• Radtke AJ, Tse SW, Zavala F. From the draining lymph node to the liver: the induction and effector mechanisms of malaria-specific CD8+ T cells. Semin Immunopathol. 2015;37(3):211–220.
   PubMed Web of Science ®Google Scholar
• Urban BC, Ferguson DJ, Pain A, et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature. 1999;400(6739):73–77.
   PubMed Web of Science ®Google Scholar
• Ocana-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med. 2003;197(2):143–151.
   PubMed Web of Science ®Google Scholar
• Minigo G, Woodberry T, Piera KA, et al. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog. 2009;5(4):e1000402.
   PubMed Web of Science ®Google Scholar
• Hansen DS, Schofield L. Natural regulatory T cells in malaria: host or parasite allies? PLoS Pathog. 2010;6(4):e1000771.
   PubMed Web of Science ®Google Scholar
• Plebanski M, Lee EA, Hannan CM, et al. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nat Med. 1999;5(5):565–571.
   PubMed Web of Science ®Google Scholar
• Plebanski M, Lee EAM, Hill AVS. Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein. Parasitology. 1997;115:S55–S66.
   PubMed Web of Science ®Google Scholar
• Zheng H, Tan ZP, Xu WY. Immune evasion strategies of pre-erythrocytic malaria parasites. Mediat Inflamm. 2014;2014:362605.
   Web of Science ®Google Scholar
• Chakravarty S, Cockburn IA, Kuk S, et al. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat Med. 2007;13(9):1035–1041.
   PubMed Web of Science ®Google Scholar
• Corradin G, Levitskaya J. Priming of CD8(+) T cell responses to liver stage malaria parasite antigens. Front Immunol. 2014;5:527.
   PubMed Web of Science ®Google Scholar
• Wykes MN, Good MF. What really happens to dendritic cells during malaria? Nat Rev Microbiol. 2008;6(11):864–870.
   PubMed Web of Science ®Google Scholar
• Elliott SR, Spurck TP, Dodin JM, et al. Inhibition of dendritic cell maturation by malaria is dose dependent and does not require Plasmodium falciparum erythrocyte membrane protein 1. Infect Immun. 2007;75(7):3621–3632.
   PubMed Web of Science ®Google Scholar
• Wykes MN, Kay JG, Manderson A, et al. Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice. Proc Natl Acad Sci U S A. 2011;108(27):11205–11210.
   PubMed Web of Science ®Google Scholar
• Plebanski M, Hannan CM, Behboudi S, et al. Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses. Immunol Cell Biol. 2005;83(3):307–312.
   PubMed Web of Science ®Google Scholar
• Plebanski M, Aidoo M, Whittle HC, et al. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J Immunol. 1997;158(6):2849–2855.
   PubMed Web of Science ®Google Scholar
• Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–532.
   PubMed Web of Science ®Google Scholar
• Mills KH, McGuirk P. Antigen-specific regulatory T cells–their induction and role in infection. Semin Immunol. 2004;16(2):107–117.
   PubMed Web of Science ®Google Scholar
• Walther M, Jeffries D, Finney OC, et al. Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparum malaria. PLoS Pathog. 2009;5(4):e1000364.
   PubMed Web of Science ®Google Scholar
• Todryk SM, Bejon P, Mwangi T, et al. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. Plos One. 2008;3(4):e2027.
   PubMed Web of Science ®Google Scholar
• Boyle MJ, Jagannathan P, Farrington LA, et al. Decline of FoxP3+ regulatory CD4 T cells in peripheral blood of children heavily exposed to malaria. PLoS Pathog. 2015;11(7):e1005041.
   PubMed Web of Science ®Google Scholar
• Ndure J, Flanagan KL. Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front Microbiol. 2014;5:477.
   PubMed Web of Science ®Google Scholar
• Moore AC, Gallimore A, Draper SJ, et al. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. J Immunol. 2005;175(11):7264–7273.
   PubMed Web of Science ®Google Scholar
• Scholzen A, Mittag D, Rogerson SJ, et al. Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathog. 2009;5(8):e1000543.
   PubMed Web of Science ®Google Scholar
• Casares S, Brumeanu TD, Richie TL. The RTS,S malaria vaccine. Vaccine. 2010;28(31):4880–4894.
   PubMed Web of Science ®Google Scholar
• Reece WH, Pinder M, Gothard PK, et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med. 2004;10(4):406–410.
   PubMed Web of Science ®Google Scholar
• Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 1991;252(5010):1308–1310.
   PubMed Web of Science ®Google Scholar
• Plebanski M, Lee EA, Hill AV. Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein. Parasitology. 1997;115(Suppl):S55–S66.
   PubMed Web of Science ®Google Scholar
• Plassmeyer ML, Reiter K, Shimp RL Jr, et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J Biol Chem. 2009;284(39):26951–26963.
   PubMed Web of Science ®Google Scholar
• Singh JP, Verma S, Bhattacharya PR, et al. Plasmodium falciparum circumsporozoite protein: epidemiological variations among field isolates prevalent in India. Trop Med Int Health. 2009;14(8):957–966.
   PubMed Web of Science ®Google Scholar
• Gandhi K, Thera MA, Coulibaly D, et al. Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg. 2012;86(5):775–781.
   PubMed Web of Science ®Google Scholar
• Alloueche A, Silveira H, Conway DJ, et al. High-throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein. Mol Biochem Parasitol. 2000;106(2):273–282.
   PubMed Web of Science ®Google Scholar
• Escalante AA, Grebert HM, Isea R, et al. A study of genetic diversity in the gene encoding the circumsporozoite protein (CSP) of Plasmodium falciparum from different transmission areas–XVI. Asembo Bay Cohort Project. Mol Biochem Parasitol. 2002;125(1–2):83–90.
   PubMed Web of Science ®Google Scholar
• Neafsey DE, Juraska M, Bedford T, et al. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Engl J Med. 2015;373(21):2025–2037.
   PubMed Web of Science ®Google Scholar
• McCutchan TF, Good MF, Miller LH. Polymorphism in the circumsporozoite (CS) protein of Plasmodium falciparum. Parasitol Today. 1989;5(5):143–146.
   PubMedGoogle Scholar
• Kumkhaek C, Phra-Ek K, Renia L, et al. Are extensive T cell epitope polymorphisms in the Plasmodium falciparum circumsporozoite antigen, a leading sporozoite vaccine candidate, selected by immune pressure? J Immunol. 2005;175(6):3935–3939.
   PubMed Web of Science ®Google Scholar
• Gandhi K, Thera MA, Coulibaly D, et al. Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications. Plos One. 2014;9(7):e101783.
   PubMed Web of Science ®Google Scholar
• Plebanski M, Flanagan KL, Lee EA, et al. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity. 1999;10(6):651–660.
   PubMed Web of Science ®Google Scholar
• Jalloh A, Jalloh M, Matsuoka H. T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: age-dependent haplotype distribution? Malar J. 2009;8:120.
   PubMed Web of Science ®Google Scholar
• Barry AE, Schultz L, Buckee CO, et al. Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. Plos One. 2009;4(12):e8497.
   PubMed Web of Science ®Google Scholar
• Qari SH, Collins WE, Lobel HO, et al. A study of polymorphism in the circumsporozoite protein of human malaria parasites. Am J Trop Med Hyg. 1994;50(1):45–51.
   PubMed Web of Science ®Google Scholar
• Gilbert SC, Plebanski M, Gupta S, et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science. 1998;279(5354):1173–1177.
   PubMed Web of Science ®Google Scholar
• Udhayakumar V, Shi YP, Kumar S, et al. Antigenic diversity in the circumsporozoite protein of Plasmodium falciparum abrogates cytotoxic-T-cell recognition. Infect Immun. 1994;62(4):1410–1413.
   PubMed Web of Science ®Google Scholar
• Udhayakumar V, Ongecha JM, Shi YP, et al. Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults. Eur J Immunol. 1997;27(8):1952–1957.
   PubMed Web of Science ®Google Scholar
• Lalvani A, Aidoo M, Allsopp CE, et al. An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum. Res Immunol. 1994;145(6):461–468.
   PubMedGoogle Scholar
• Hill AV, Allsopp CE, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature. 1991;352(6336):595–600.
   PubMed Web of Science ®Google Scholar
• Kijak GH, Walsh AM, Koehler RN, et al. HLA class I allele and haplotype diversity in Ugandans supports the presence of a major east African genetic cluster. Tissue Antigens. 2009;73(3):262–269.
   PubMed Web of Science ®Google Scholar
• Zevering Y, Khamboonruang C, Good MF. Human and murine T-cell responses to allelic forms of a malaria circumsporozoite protein epitope support a polyvalent vaccine strategy. Immunology. 1998;94(3):445–454.
   PubMed Web of Science ®Google Scholar
• Hill AV, Reyes-Sandoval A, O’Hara G, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin. 2010;6(1):78–83.
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Ewer KJ, Bliss CM, et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis. 2015;211(7):1076–1086.
   PubMed Web of Science ®Google Scholar
• Hafalla JC, Bauza K, Friesen J, et al. Identification of targets of CD8(+) T cell responses to malaria liver stages by genome-wide epitope profiling. PLoS Pathog. 2013;9(5):e1003303.
   PubMed Web of Science ®Google Scholar
• Wizel B, Houghten RA, Parker KC, et al. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med. 1995;182(5):1435–1445.
   PubMed Web of Science ®Google Scholar
• Aidoo M, Lalvani A, Allsopp CE, et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet. 1995;345(8956):1003–1007.
   PubMed Web of Science ®Google Scholar
• Gonzalez JM, Peter K, Esposito F, et al. HLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new Plasmodium falciparum epitopes by IFN-gamma ELISPOT. Parasite Immunol. 2000;22(10):501–514.
   PubMed Web of Science ®Google Scholar
• Dodoo D, Hollingdale MR, Anum D, et al. Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. Malar J. 2011;10:168.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, Mwangi T, Plebanski M, et al. Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am J Trop Med Hyg. 2003;68(4):421–430.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, Plebanski M, Akinwunmi P, et al. Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of Plasmodium falciparum in West Africans. Eur J Immunol. 1999;29(6):1943–1954.
   PubMed Web of Science ®Google Scholar
• Wang R, Charoenvit Y, Corradin G, et al. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes. J Immunol. 1996;157(9):4061–4067.
   PubMed Web of Science ®Google Scholar
• Khusmith S, Charoenvit Y, Kumar S, et al. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science. 1991;252(5006):715–718.
   PubMed Web of Science ®Google Scholar
• Khusmith S, Sedegah M, Hoffman SL. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun. 1994;62(7):2979–2983.
   PubMed Web of Science ®Google Scholar
• Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med. 1998;4(4):397–402.
   PubMed Web of Science ®Google Scholar
• Ewer KJ, O’Hara GA, Duncan CJ, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013;4:2836.
   PubMed Web of Science ®Google Scholar
• Robson KJ, Hall JR, Davies LC, et al. Polymorphism of the TRAP gene of Plasmodium falciparum. Proc Biol Sci. 1990;242(1305):205–216.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, Plebanski M, Odhiambo K, et al. Cellular reactivity to the P. falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am J Trop Med Hyg. 2006;74(3):367–375.
   PubMed Web of Science ®Google Scholar
• Mwacharo J, Dunachie SJ, Kai O, et al. Quantitative PCR evaluation of cellular immune responses in Kenyan children vaccinated with a candidate malaria vaccine. Plos One. 2009;4(12):e8434.
   PubMed Web of Science ®Google Scholar
• Kester KE, Gray Heppner D Jr, Moris P, et al. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naive adults. Vaccine. 2014;32(49):6683–6691.
   PubMed Web of Science ®Google Scholar
• Bucci K, Kastens W, Hollingdale MR, et al. Influence of age and HLA type on interferon-gamma (IFN-gamma) responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1 (LSA-1). Clin Exp Immunol. 2000;122(1):94–100.
   PubMed Web of Science ®Google Scholar
• Ravichandran M, Doolan DL, Cox-Singh J, et al. Research note: HLA degenerate T-cell epitopes from Plasmodium falciparum liver stage-specific antigen 1 (LSA-1) are highly conserved in isolates from geographically distinct areas. Parasite Immunol. 2000;22(9):469–473.
   PubMed Web of Science ®Google Scholar
• Prieur E, Druilhe P. The malaria candidate vaccine liver stage antigen-3 is highly conserved in Plasmodium falciparum isolates from diverse geographical areas. Malar J. 2009;8:247.
   PubMed Web of Science ®Google Scholar
• Jongwutiwes S, Putaporntip C, Karnchaisri K, et al. Positive selection on the Plasmodium falciparum sporozoite threonine-asparagine-rich protein: analysis of isolates mainly from low endemic areas. Gene. 2008;410(1):139–146.
   PubMed Web of Science ®Google Scholar
• Bongartz M, Rezbach P, Borrmann S, et al. Age-dependent enhancement of IFN-gamma responses to Plasmodium falciparum liver stage antigen-1 T cell epitopes. Parasitol Res. 2002;88(12):1083–1089.
   PubMed Web of Science ®Google Scholar
• John CC, Sumba PO, Ouma JH, et al. Cytokine responses to Plasmodium falciparum liver-stage antigen 1 vary in rainy and dry seasons in highland Kenya. Infect Immun. 2000;68(9):5198–5204.
   PubMed Web of Science ®Google Scholar
• Aidoo M, Lalvani A, Gilbert SC, et al. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infect Immun. 2000;68(1):227–232.
   PubMed Web of Science ®Google Scholar
• Aidoo M, Udhayakumar V. Field studies of cytotoxic T lymphocytes in malaria infections: implications for malaria vaccine development. Parasitol Today. 2000;16(2):50–56.
   PubMedGoogle Scholar
• Flanagan KL, van Crevel R, Curtis N, et al. Heterologous (‘nonspecific’) and sex-differential effects of vaccines: epidemiology, clinical trials, and emerging immunologic mechanisms. Clin Infect Dis. 2013;57(2):283–289.
   PubMed Web of Science ®Google Scholar
• Benn CS, Netea MG, Selin LK, et al. A small jab - a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 2013;34(9):431–439.
   PubMed Web of Science ®Google Scholar
• Aaby P, Roth A, Ravn H, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011;204(2):245–252.
   PubMed Web of Science ®Google Scholar
• Aaby P, Martins CL, Garly ML, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. Brit Med J. 2010;341:c6495.
   PubMed Web of Science ®Google Scholar
• Aaby P, Benn C, Nielsen J, et al. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. BMJ Open. 2012;2(3):e000707.
   Web of Science ®Google Scholar
• Flanagan KL, Klein SL, Skakkebaek NE, et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine. 2011;29(13):2349–2354.
   PubMed Web of Science ®Google Scholar
• Welsh RM, Che JW, Brehm MA, et al. Heterologous immunity between viruses. Immunol Rev. 2010;235(1):244–266.
   PubMed Web of Science ®Google Scholar
• Gil A, Kenney LL, Mishra R, et al. Vaccination and heterologous immunity: educating the immune system. Trans R Soc Trop Med Hyg. 2015;109(1):62–69.
   PubMed Web of Science ®Google Scholar
• Mathurin KS, Martens GW, Kornfeld H, et al. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol. 2009;83(8):3528–3539.
   PubMed Web of Science ®Google Scholar
• Tinto H, D’Alessandro U, Sorgho H, et al. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31–45.
   PubMed Web of Science ®Google Scholar
• Aaby P, Rodrigues A, Kofoed PE, et al. RTS,S/AS01 malaria vaccine and child mortality. Lancet. 2015;386(10005):1735–1736.
   PubMed Web of Science ®Google Scholar
• Cohen J, Nussenzweig V, Nussenzweig R, et al. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin. 2010;6(1):90–96.
   PubMed Web of Science ®Google Scholar
• de la Cruz VF, Maloy WL, Miller LH, et al. Lack of cross-reactivity between variant T cell determinants from malaria circumsporozoite protein. J Immunol. 1988;141(7):2456–2460.
   PubMed Web of Science ®Google Scholar
• Epstein JE, Richie TL. The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review. Curr Opin Infect Dis. 2013;26(5):420–428.
   PubMed Web of Science ®Google Scholar
• Richie TL, Billingsley PF, Sim BK, et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015. [Epub ahead of print]. doi:10.1016/j.vaccine.2015.09.096
   Web of Science ®Google Scholar
• Bijker EM, Borrmann S, Kappe SH, et al.. Novel approaches to whole sporozoite vaccination against malaria. Vaccine. 2015. [Epub ahead of print]. doi:10.1016/j.vaccine.2015.09.095
   PubMed Web of Science ®Google Scholar
• Rivoltini L, Squarcina P, Loftus DJ, et al. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res. 1999;59(2):301–306.
   PubMed Web of Science ®Google Scholar
• Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001;98(15):8809–8814.
   PubMed Web of Science ®Google Scholar
• Hoppes R, Oostvoges R, Luimstra JJ, et al. Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes. J Immunol. 2014;193(10):4803–4813.
   PubMed Web of Science ®Google Scholar
• Wilson KL, Xiang SD, Plebanski M. Montanide, Poly I:C and nanoparticle based vaccines promote differential suppressor and effector cell expansion: a study of induction of CD8 T cells to a minimal Plasmodium berghei epitope. Front Microbiol. 2015;6:29.
   PubMed Web of Science ®Google Scholar